The short answer
The Zagreb group named the gastric juice protein body protection compound to reflect a hypothesised protective role. The name records a hypothesis from the time of discovery rather than a demonstrated function, and it has carried an implicit claim ever since.
Key facts
- Named by
- The Zagreb research group
- Refers to
- A protein in human gastric juice
- BPC-157
- A 15-residue partial sequence of it
- The name asserts
- A protective function
- Status of that claim
- Preclinical; one Phase 2 recruiting
- Comparable case
- Delta sleep-inducing peptide
The reasoning behind the name
Gastric juice is a hostile environment (strongly acidic and rich in proteases), and the stomach lining survives it. That observation invites the hypothesis that something in gastric juice is protective, and a protein isolated from it that appeared to have protective effects in lesion models was named accordingly.
What a functional name does to a reader
It supplies a conclusion before any evidence is examined. Body protection compound sounds like a description; it is a proposal. The same is true of delta sleep-inducing peptide, and of liver cell growth factor, GHK's original name. All three were named for what an investigator believed they had found. Two of those names did not survive scrutiny.
Research material referenced
BPC-157 5mg, third-party HPLC tested
How BPC-157 differs from those cases
It has more behind it. DSIP has no gene, no receptor and an unresolved central claim. GHK's early name was abandoned once its actual chemistry became clear. BPC-157 has a large preclinical literature across multiple model systems, earlier clinical development as PL-14736, and a randomised placebo-controlled Phase 2 recruiting now. The name is still a hypothesis, but the hypothesis is being tested properly.
What would settle it
NCT07437547: a randomised, double-blind, placebo-controlled Phase 2 trial in 120 participants with acute hamstring strain, sponsored by a party unconnected to the original research group, with primary completion due 14 February 2027. That design is what converts a hypothesis into a result, whichever direction it goes.
The position until then
The name is not evidence. The preclinical literature is substantial but concentrated in one group. The clinical evidence is a completed Phase 1 and a Phase 2 that has not reported. That is an interesting position for a research compound to be in, and it is not the same as a demonstrated protective effect in anyone.
Frequently asked questions
Does the name mean BPC-157 protects the body?
No. It records a hypothesis the Zagreb group formed at discovery. Names of that kind assert a function rather than describe a demonstrated one.
Is the hypothesis being tested?
Yes. NCT07437547 is a randomised, double-blind, placebo-controlled Phase 2 trial with primary completion due February 2027.
How does this compare to DSIP?
Both are named for a proposed function. DSIP has no gene, no receptor and no clinical programme; BPC-157 has a large preclinical literature and registered trials.
Continue researching
Peer-reviewed guides, comparators and matched reference materials.
Primary sources & clinical trials
Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.
- TrialClinicalTrials.gov: BPC 157 Phase 2 (NCT07437547)clinicaltrials.gov
- PubMedSikiric P et al. Curr Pharm Des 2011 (PMID 21548867)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., BPC 157 in trials for IBD. Inflammopharmacology 2006 (PMID 17186181)pubmed.ncbi.nlm.nih.gov
- PubMedSikiric P et al., Fistulas Healing: Stable Gastric Pentadecapeptide BPC 157 Therapy. Curr Pharm Des 2020 (PMID 32329684)pubmed.ncbi.nlm.nih.gov
- PubMedKrivic A et al., Achilles detachment in rat and stable gastric pentadecapeptide BPC 157. J Orthop Res 2006 (PMID 16583442)pubmed.ncbi.nlm.nih.gov
- PubMedCerovecki T et al., Pentadecapeptide BPC 157 improves ligament healing in the rat. J Orthop Res 2010 (PMID 20225319)pubmed.ncbi.nlm.nih.gov
- PubMedSeiwerth S et al., BPC 157 and blood vessels. Curr Pharm Des 2014 (PMID 23782145)pubmed.ncbi.nlm.nih.gov
- PubChemPubChem · BPC-157 (CID 9941957)pubchem.ncbi.nlm.nih.gov
- GuidelineGoogle: Creating helpful, reliable, people-first contentdevelopers.google.com
Browse the wider literature
Live database searches, not fixed citations. Results change as new work is indexed.
Written and reviewed by
William Heath · Editor, UK Peptides research library
William Heath edits the UK Peptides research library. He is responsible for what is published here: every article is sourced to primary literature, every purity or identity statement traces to a signed third-party certificate for a specific lot, and corrections are made in place with the review date updated. No scientific or medical credentials are claimed on this site; the evidence is carried by the cited sources and the certificates, not by the byline.
More BPC-157 (Pentadecapeptide) articles
- The Gastric Juice OriginBPC-157 is a partial sequence of a protein identified in human gastric juice. What that means, and what it does not mean about the peptide itself.
- The Stability Claim, ExaminedThe literature calls it the stable gastric pentadecapeptide. What stability means here, what supports the claim, and what it does not imply.
- BPC-157 Storage, Stability and ReconstitutionProline-rich and free of cysteine and methionine, so enzymatically and chemically robust. Why gastric stability does not remove the need for cold, dry storage.
- BPC-157 Mechanism: Why It Is Described as Multi-PathwayReported effects span angiogenic signalling, growth-factor interactions and nitric oxide pathways. Why no single defining mechanism has emerged.
- BPC-157 and Blood VesselsVascular effects recur across the BPC-157 literature and offer the most plausible common thread linking its reported activity in different tissues.